A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.
Saved in:
| Title: | A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT. |
|---|---|
| Authors: | Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS., DiPersio JF; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO., Azzi J; Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY., Cooper BW; Adult Hematologic Malignancies and Stem Cell Transplant, Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH., Koehne G; Miami Cancer Institute, Baptist Health South Florida, Miami, FL., Koura D; University of California San Diego Moores Cancer Center, San Diego, CA., Maakaron J; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Magenau J; Department of Internal Medicine, University of Michigan, Ann Arbor, MI., McClune B; Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT., Rimando JC; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA., Shah NN; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD., Suh HC; Division of Hematology Oncology, Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ., Beuka K; Vor Biopharma, Cambridge, MA., Sturrock J; Vor Biopharma, Cambridge, MA., Nikam M; Vor Biopharma, Cambridge, MA., Berglund E; Vor Biopharma, Cambridge, MA., Hu J; Vor Biopharma, Cambridge, MA., Keschner Y; Vor Biopharma, Cambridge, MA., Etchin J; Vor Biopharma, Cambridge, MA., Lydeard JR; Vor Biopharma, Cambridge, MA., Vasquez M; Vor Biopharma, Cambridge, MA., O'Donnell D; Vor Biopharma, Cambridge, MA., Mundelboim G; Vor Biopharma, Cambridge, MA., Thosar S; Vor Biopharma, Cambridge, MA., Canesin G; Vor Biopharma, Cambridge, MA., Xavier-Ferrucio J; Vor Biopharma, Cambridge, MA., Hyzy SL; Vor Biopharma, Cambridge, MA., Lloyd DM; Vor Biopharma, Cambridge, MA., Spink K; Vor Biopharma, Cambridge, MA., Hummel D; Vor Biopharma, Cambridge, MA., Lee-Sundlov MM; Vor Biopharma, Cambridge, MA., Scherer J; Vor Biopharma, Cambridge, MA., Lin MI; Vor Biopharma, Cambridge, MA., Whangbo JS; Vor Biopharma, Cambridge, MA., Muffly LS; Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Palo Alto, CA. |
| Source: | Blood [Blood] 2026 Apr 23; Vol. 147 (17), pp. 1914-1927. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
